2026/11/04
On November 02, 2026, the World Health Organization (WHO) confirmed that Anflu, a trivalent split-virion influenza vaccine manufactured by SINOVAC, is prequalified. Anflu is the fourth SINOVAC vaccine
On October 14, 2026, SNA01 Injection, a Category 1 innovative drug jointly submitted for clinical trial authorization by SINOVAC and the Institute of Biophysics, Chinese Academy of Sciences (CAS), rec
2026/10/15
On September 28, SINOVAC and Egypt’s GENNVAX launched a technology transfer project for Poliomyelitis Vaccine, Inactivated, Sabin Strains (sIPV) at an event in Beijing. The launch marks the start of t
2026/09/28
The 27th Annual General Meeting of the Developing Countries Vaccine Manufacturers Network (DCVMN) opened in Beijing on September 22, 2026, under the theme "Transforming Innovation into Immunizati
2026/09/23
The content is intended for use by media professionals
These images may be downloaded for non-commercial use and for purposes such as news reporting or research. Images may not be modified and must display the following copyright language: Copyright © SINOVAC Biotech Ltd. All rights reserved.
Learn more about SINOVAC copyright and trademark policies.
Media Contacts: pr@sinovac.com
EN
